Loading stock data…
Loading stock data…
US$1.15
Get one email when ARTL crosses your level. Checked every 15 minutes during market hours.
▲ +0.01 (0.88%)up today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
41.1
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
-0.13
Bullish momentumMACD above its signal line (-0.18).
50-day average
1.44
Price belowShort-term trend reference.
200-day average
4.95
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist in Phase 1b/2a clinical trials for treating cancer-related anorexia and weight loss. ART12.11, a proprietary cannabidiol cocrystal with tetramethylpyrazine, targets anxiety, depress…
artelobio.com0 strong buy · 0 buy · 3 hold · 1 sell · 2 strong sell (6 analysts, 2026-07-01)
0 strong buy · 0 buy · 3 hold · 1 sell · 2 strong sell (6 analysts, 2026-06-01)
0 strong buy · 0 buy · 3 hold · 1 sell · 2 strong sell (6 analysts, 2026-05-01)
0 strong buy · 0 buy · 3 hold · 1 sell · 2 strong sell (6 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-02-24 | -4.71 | -0.12 | ✓ Beat |
| 2026-01-15 | 2.98 | 3.14 | ✓ Beat |
| 2025-11-28 | 2.94 | 2.57 | ✗ Miss |
| 2025-11-12 | -2.46 | -11.91 | ✗ Miss |
| 2025-10-23 | -0.3 | -0.19 | ✓ Beat |
| 2025-08-13 | -12.57 | -16.83 | ✗ Miss |
| 2025-05-13 | -2.34 | -12.96 | ✗ Miss |
| 2025-03-03 | -6.84 | -21.06 | ✗ Miss |
Companies in the same industry, via Finnhub